Under the new policy, financial assistance has been increased to Rs 50 lakh per patient to improve treatment access
Approval for generic Ozempic® in Canada strengthens OneSource’s global CDMO footprint in complex peptide injectable manufacturing
Market authorization for generic GLP-1 therapy strengthens company’s diabetes portfolio in Canada
Wadhwa brings over two decades of experience driving growth, transformation, and customer-centric strategies in the medical devices and diagnostics sector
Both join the leading CRDMO’s executive committee to drive global people strategy and commercial expansion
Steady growth led by biologics and CRDMO business, EBITDA margin at 25% with continued investments in ADCs, peptides, and digital capabilities
Approval for generic Semaglutide Injection strengthens CDMO partnership, enabling scalable supply from OneSource’s US FDA-approved Bengaluru facility
Deploys $40 million in Hyderabad; advances APIs, peptides, and global small molecule capabilities
_256_384.jpg)
The approval makes Cipla’s product the first AB-rated generic therapeutic equivalent of Ventolin HFA
Approval for Albuterol Sulfate inhalation aerosol enables Cipla Limited to enter the $1.5 billion U.S. albuterol market
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
